The customs detention question comes up constantly and almost every answer treats it as a single variable: will my package get seized or not. That’s the wrong frame. What actually determines exposure is how the specific compound is classified at the point of entry, and that varies more than most people realize. A few things that affect seizure likelihood differently: Compound class: BPC or TB-500 are research chemicals with no scheduled analog in most jurisdictions. GHK-Cu is a cosmetic ingredient sold openly in skincare. MK-677 is an investigational drug with a more complicated import status in several countries. Customs officers aren’t pharmacologists, but automated systems flag compounds against controlled substance databases, and the hits are not distributed evenly across peptide classes. Form factor: Lyophilized powder in an unlabeled vial reads differently at inspection than something packaged to resemble a finished pharmaceutical. Raw powder is harder to positively identify. Country pair: US-to-Canada vs. China-to-US customs exposure is not the same problem. Canada has specific Health Canada rules around unapproved therapeutic drugs that make international research chemical imports meaningfully riskier than equivalent US imports from the same supplier. Order size and declared value: A $200 single-compound order implies personal use at a scale that draws more scrutiny than a $40 curiosity order. This isn’t arbitrary, larger quantities suggest intent beyond casual research. The supplier saying “nothing we can do” is accurate but not useful. The better question before ordering: what is this compound’s regulatory status in my specific jurisdiction, and does this supplier have a domestic option. Those two answers change the risk calculus more than anything else.
eta: one more thing
The MK-677 distinction is worth expanding. It’s had active IND applications with the FDA, which means it exists in actual regulatory databases in a way that BPC-157 simply doesn’t. That’s a different category of attention if something goes sideways downstream, not just a marginally higher seizure probability. “Complicated import status” is the polite version of what that actually means. On the Canada point specifically: Health Canada maintains a publicly searchable Unauthorized Health Products database, and it’s worth 10 minutes before any cross-border order. A handful of peptides show up there explicitly, and the list has grown. The declared value asymmetry also has real numbers behind it. Canada’s de minimis threshold for formal customs processing is a fraction of the US threshold ($800 as of 2016), which is a big part of why the same supplier, same compound, same quantity gets treated differently depending on which direction the package is moving. The “order smaller to reduce scrutiny” advice holds much better domestically than it does for US-to-Canada or China-to-US routes, where the volume discount in risk just doesn’t work the same way.
Ask suppliers about their seizure rate on that specific route before ordering. That’s your actual baseline, way more predictive than regulatory class.
eta: one more thing
The IND point is one I keep having to explain to people who lump all peptides into “research chemical” as if that’s a uniform category. FDA’s own regulatory database having a record of the compound means the theoretical pathway from seized package to something worse than a loss letter is shorter, even if that path is rarely traveled. The Health Canada unauthorized products check is exactly right as a pre-order step; I’d add that recent enforcement actions against specific suppliers matter as much as whether the compound itself is listed, and the list won’t tell you that part.
The domestic compounding pharmacy route is the third option this framing keeps leaving out.
imo Through 2023, certain peptides including BPC were accessible via 503A compounders in the US with a valid prescription, which made the customs question irrelevant for those compounds entirely. FDA’s 2024 bulk substances guidance pulled that option for several research-adjacent peptides, but it’s worth reading that guidance in the other direction: the compounds that got removed from compounding eligibility are exactly the ones with higher regulatory profile, and that same profile elevation is a signal about customs exposure for international imports of the same compounds. So the FDA compounder list isn’t just an access question, it functions as a rough proxy for “how much does this agency care about this molecule right now.” The compounds that got grandfathered into continued compounding eligibility vs. the ones that didn’t are not a random draw, and that distinction maps pretty cleanly onto the risk tiers OP is describing.
You nailed the part everyone skips. Most folks ask ‘will it get through’ when they should be asking what this specific compound looks like in their specific country. I found this out the hard way. First cycle I ordered BPC and TB-500 from the same supplier. BPC cleared in three days. TB-500 sat for a week. Same declared value, completely different regulatory flags at entry. After that I started calling before ordering to ask what they could actually ship domestic. Changed everything
You can’t decide without baseline data: your country’s regulatory stance on the compound, plus your supplier’s seizure rate on that specific route. Before ordering, ask suppliers point-blank: documented seizure rate on shipments to my jurisdiction, and whether they have a domestic backup for delays. If they don’t have both answers, they don’t understand their own risk profile. Source domestically instead. Either way, this conversation clears it up: you find out if the import is viable or you source from someone who actually knows. Numbers don’t lie.